This Diagnostic stock which deals in the business of consumer healthcare brands in diagnostic services with an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services was up 5 percent after the Multi-Manager ICVC sold their stake through Bulk deal.
Price Action
With a market capitalization of Rs. 26,114.06 Crores, the shares of Dr. Lal PathLabs Ltd (NS:DLPA) were up by 4.7 percent touching a day’s high of Rs. 3,143.90 per share. The stock reiterated from the day’s high and was trading at Rs. 3,124.15 per share which is 4.12 percent higher from the previous closing price of Rs. 3000.45 apiece. The stock has delivered a return of 24 percent over the past year and outperformed the Nifty Index.
Don’t miss out on today’s opportunities—equip yourself with InvestingPro and take advantage of our Black Friday offer to stay ahead.
What Happened
The movement in stock price was due to the bulk deal on 06th January 2025. The seller name Multi-Manager ICVC has sold its equity shares of 4,34,943 with an average share price of Rs. 2,997.11 per share.
About the Company
Dr. Lal PathLabs was founded in 1949. It is a leading Indian diagnostic and healthcare service provider headquartered in Gurugram. The company operates over 200 laboratories and 5,000 collection centers across India, offering a wide range of tests, including blood, urine, and specialized diagnostics. Their business model focuses on direct-to-consumer services, hospital partnerships, and home collection for convenience. Revenue is generated through diagnostic testing and preventive health check-ups. Dr. Lal PathLabs focuses on quality with multiple accreditations and aims to expand its reach through strategic acquisitions and technological advancements in healthcare diagnostics.
Financials & Ratios
Its Revenue from operations increased by 9.81 percent year on year from Rs. 601 Crores in Q2FY24 to Rs. 660 Crores in Q2FY25, accompanied by profits of Rs. 111 Crores to Rs. 131 Crores.
In the return ratios, the return on equity (RoE) in FY24 stood at around 20.61 percent, and the return on capital employed was around 25.58 percent. The debt-to-equity ratio stood around 0.19 as of FY24.
Shareholding Pattern
As of September 2024, the shareholding pattern with the promoter’s stake holding a share of 53.92 percent in Dr. Lal Path Labs, Foreign Institutional Investors (FII) holding around 26.82 percent, Domestic Institutional Investors (DII) holding around 12.89 percent, and the public holding around 6.37 percent.
Written by Santhosh S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Healthcare stock jumps 5% after Multi-manager ICVC sold 4,34,943 share in the company appeared first on Trade Brains.
To understand more about InvestingPro, watch this video: https://www.youtube.com/watch?v=_WfQcN5vjI